STOCK TITAN

Atlantic Coastal Acquisition Corp. II - ACAB STOCK NEWS

Welcome to our dedicated page for Atlantic Coastal Acquisition II news (Ticker: ACAB), a resource for investors and traders seeking the latest updates and insights on Atlantic Coastal Acquisition II stock.

Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) provides investors with comprehensive access to official company announcements and market-moving developments. This dedicated news hub aggregates all regulatory filings, merger updates, and strategic initiatives related to this special purpose acquisition company.

Our curated collection enables efficient tracking of ACAB's progress in identifying acquisition targets, maintaining Nasdaq compliance, and executing its SPAC mandate. Users will find timely updates including SEC filings, leadership statements, and material event disclosures.

The resource prioritizes verified information from primary sources, focusing on merger timelines, capital structure changes, and corporate governance matters. All content maintains strict neutrality regarding investment merits while providing the factual foundation for informed analysis.

Bookmark this page for streamlined monitoring of ACAB's regulatory submissions and acquisition progress. Regular updates ensure stakeholders remain informed about this SPAC's evolving position in the mergers and acquisitions landscape.

Rhea-AI Summary

Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) received a notification from Nasdaq on June 3, 2024, indicating non-compliance with listing requirements due to a delayed filing of its Quarterly Report on Form 10-Q for the period ending March 31, 2024. This notification does not immediately affect the listing of the company's securities. The company has 60 days to present a compliance plan to Nasdaq and is working to finalize the financial statements to file the 10-Q in the upcoming weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Atlantic Coastal Acquisition Corp. II extends time for business combination
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Abpro and Atlantic Coastal Acquisition Corp. II announce a term sheet for a business combination, valuing Abpro at $725 million. The transaction is expected to close in Q2 2024 and will help advance Abpro's drug pipeline to clinical trials. Abpro is currently focusing on developing next-generation antibody therapies for HER2+ cancer treatments and COVID-19.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
Rhea-AI Summary
Atlantic Coastal Acquisition Corp. (NASDAQ: ACAH) has filed a Definitive Proxy Statement to extend the time for a business combination. The statement includes information on the company's eligibility to be listed on Nasdaq, corrections of figures from the Preliminary Proxy Statement, details on the liquidation of securities in the Trust Account, and a modified deadline for stockholders to redeem their Class A common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary
Atlantic Coastal Acquisition Corp. extends deadline for business combination, subject to shareholder approval on September 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Atlantic Coastal Acquisition Corp. (NASDAQ: ACAH) will redeem all outstanding shares of Class A common stock due to failure to complete an initial business combination. The per-share redemption price is expected to be approximately $10.40. The Company's securities will cease trading on Nasdaq on August 18, 2023. No redemption rights or liquidating distributions will be given for warrants. The Company expects delisting and termination of securities registration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Atlantic Coastal Acquisition Corp. II

Nasdaq:ACAB

ACAB Rankings

ACAB Stock Data

84.35M
591.27k
92.65%
7.21%
0.04%
Shell Companies
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK